Therapy for locally advanced adenocarcinoma of the gastroesophageal junction: Optimizing outcome

Seminars in Radiation Oncology

Volumn 23, Issue 1, 2013, Pages 38-50

  Kleinberg, Lawrence ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLATINUM; TRASTUZUMAB; VINBLASTINE;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GASTROINTESTINAL CARCINOMA; HISTOPATHOLOGY; HUMAN; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; STOMACH CANCER; TUMOR CLASSIFICATION;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; NEOADJUVANT THERAPY; STOMACH NEOPLASMS;

EID: 84874422993     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2012.10.001     Document Type: Article

References (58)

1. Blot W.J., Devesa S.S., Kneller R.W., et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991, 265:1287-1289.
2. Yee Y.K., Wong B.C. Adenocarcinoma of the esophagogastric junction: Do we see more or less?. J Gastroenterol Hepatol 2008, 23:1627-1628.
3. Devesa S.S., Blot W.J., Stone B.J., et al. Recent cancer trends in the united states. J Natl Cancer Inst 1995, 87:175-182.
4. Devesa S.S., Blot W.J., Fraumeni J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the united states. Cancer 1998, 83:2049-2053.
5. Freedman N.D., Abnet C.C., Leitzmann M.F., et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007, 165:1424-1433.
6. Lagergren J., Bergström R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999, 340:825-831.
7. Tejani M.A., Burtness B.A. Multi-modality therapy for cancer of the esophagus and GE junction. Curr Treat Options Oncol 2012, 13:390-402.
8. van Hagen P., Hulshof M.C., van Lanschot J.J., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012, 366:2074-2084.
9. Urba S.G., Orringer M.B., Turrisi A., et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001, 19:305-313.
10. Hulscher J.B., van Lanschot J.J. Individualised surgical treatment of patients with an adenocarcinoma of the distal oesophagus or gastro-oesophageal junction. Dig Surg 2005, 22:130-134.
11. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002, 359:1727-1733. Medical Research Council Oesophageal Cancer Working Group.
12. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20.
13. Ychou M., Boige V., Pignon J.P., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011, 29:1715-1721.
14. Smalley S.R., Benedetti J.K., Haller D.G., et al. Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012, 30:2327-2333.
15. Tepper J., Krasna M.J., Niedzwiecki D., et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008, 26:1086-1092.
16. Kleinberg L., Catalano P., Forastiere A. Long-term survival outcome of E1201: An eastern cooperative oncology group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. J Clin Oncol 2012, 30(suppl 4):69.
17. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
18. Siewert J.R., Stein H.J., Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Surg 2006, 95:260-269.
19. Siewert J.R., Hölscher A.H., Becker K., et al. Cardia cancer: Attempt at a therapeutically relevant classification [in German]. Chirurg 1987, 58:25-32.
20. Feith M., Stein H.J., Siewert J.R. Adenocarcinoma of the esophagogastric junction: Surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am 2006, 15:751-764.
21. Rice T.W., Blackstone E.H., Rusch V.W. 7th edition of the AJCC cancer staging manual: Esophagus and esophagogastric junction. Ann Surg Oncol 2010, 17:1721-1724.
22. Rusch V.W., Rice T.W., Crowley J., et al. The seventh edition of the American Joint Committee on Cancer/International Union Against Cancer staging manuals: The new era of data-driven revisions. J Thorac Cardiovasc Surg 2010, 139:819-821.
23. Gertler R., Stein H.J., Langer R., et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: Evaluation of the new union internationale contre le cancer/American joint cancer committee staging system. Ann Surg 2011, 253:689-698.
24. Leers J.M., DeMeester S.R., Chan N., et al. Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg 2009, 138:594-602. discussion 601-602.
25. Rice T.W., Rusch V.W., Apperson-Hansen C., et al. Worldwide esophageal cancer collaboration. Dis Esophagus 2009, 22:1-8.
26. Rice T.W., Rusch V.W., Ishwaran H., et al. Cancer of the esophagus and esophagogastric junction: Data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer cancer staging manuals. Cancer 2010, 116:3763-3773.
27. Leers J.M., DeMeester S.R., Oezcelik A., et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg 2011, 253:271-278.
28. Stein H.J., Feith M., Bruecher B.L., et al. Early esophageal cancer: Pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005, 242:566-573. discussion 573-575.
29. Raja S., Rice T.W., Goldblum J.R., et al. Esophageal submucosa: The watershed for esophageal cancer. J Thorac Cardiovasc Surg 2011, 142:1403-57511.e1.
30. DiMusto P.D., Orringer M.B. Transhiatal esophagectomy for distal and cardia cancers: Implications of a positive gastric margin. Ann Thorac Surg 2007, 83:1993-1998. discussion 1998-1999.
31. Omloo J.M., Lagarde S.M., Hulscher J.B., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: Five-year survival of a randomized clinical trial. Ann Surg 2007, 246:992-1000. discussion 1000-1001.
32. Sasako M., Sano T., Yamamoto S., et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: A randomised controlled trial. Lancet Oncol 2006, 7:644-651.
33. Luketich J.D., Pennathur A., Awais O., et al. Outcomes after minimally invasive esophagectomy: Review of over 1000 patients. Ann Surg 2012, 256:95-103.
34. Biere S.S., van Berge Henegouwen M.I., Maas K.W., et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: A multicentre, open-label, randomised controlled trial. Lancet 2012, 379:1887-1892.
35. Dantoc M., Cox M.R., Eslick G.D. Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: A meta-analysis. Arch Surg 2012, 147:768-776.
36. Kelsen D.P., Winter K.A., Gunderson L.L., et al. Long-term results of RTOG trial 8911 (USA intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007, 25:3719-3725.
37. Kelsen D.P., Ginsberg R., Pajak T.F., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998, 339:1979-1984.
38. Allum W.H., Stenning S.P., Bancewicz J., et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009, 27:5062-5067.
39. Stahl M., Walz M.K., Stuschke M., et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009, 27:851-856.
40. Walsh T.N., Noonan N., Hollywood D., et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335:462-467.
41. Burmeister B.H., Smithers B.M., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol 2005, 6:659-668.
42. Tillman G.F., Pawlicki T., Koong A.C., et al. Preoperative versus postoperative radiotherapy for locally advanced gastroesophageal junction and proximal gastric cancers: A comparison of normal tissue radiation doses. Dis Esophagus 2008, 21:437-444.
43. Paoletti X., Oba K., et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. JAMA 2010, 303:1729-1737. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group.
44. Sjoquist K.M., Burmeister B.H., Smithers B.M., et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol 2011, 12:681-692.
45. Burmeister B.H., Thomas J.M., Burmeister E.A., et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus?. A randomised phase II trial. Eur J Cancer 2011, 47:354-360.
46. RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer who are treated without surgery.
47. RTOG 1010: A phase III trial evaluating the addition of trastuzumab to trimodality treatment of Her2-overexpressing esophageal adenocarcinoma.
48. CALGB 80803: Phase II randomized study of PET scan-directed combined modality therapy in patients with esophageal cancer receiving FOLFOX-6 chemotherapy versus paclitaxel and carboplatin.
49. Van Cutsem E., Van de Velde C., Roth A., et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European organisation for research and treatment of cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 2008, 44:182-194.
50. Yang G.Y., McClosky S.A., Khushalani N.I. Principles of modern radiation techniques for esophageal and gastroesophageal junction cancers. Gastrointest Cancer Res 2009, 3(2 suppl):S6-S10.
51. Matzinger O., Gerber E., Bernstein Z., et al. EORTC-ROG expert opinion: Radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol 2009, 92:164-175.
52. Whitfield G.A., Jackson A., Moore C., et al. Radical chemoradiotherapy for adenocarcinoma of the distal oesophagus and oesophagogastric junction: What planning margins should we use?. Br J Radiol 2008, 81:921-934.
53. Minsky B.D., Pajak T.F., Ginsberg R.J., et al. INT 0123 Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20:1167-1174.
54. Gao X.S., Qiao X., Wu F., et al. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys 2007, 67:389-396.
55. Zhang X., Zhao K.L., Guerrero T.M., et al. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 2008, 72:278-287.
56. Zhao K.L., Liao Z., Bucci M.K., et al. Evaluation of respiratory-induced target motion for esophageal tumors at the gastroesophageal junction. Radiother Oncol 2007, 84:283-289.
57. Yaremko B.P., Guerrero T.M., McAleer M.F., et al. Determination of respiratory motion for distal esophagus cancer using four-dimensional computed tomography. Int J Radiat Oncol Biol Phys 2008, 70:145-153.
58. Li T., Schreibmann E., Thorndyke B., et al. Radiation dose reduction in four-dimensional computed tomography. Med Phys 2005, 32:3650-3660.